# Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

> **NCT02014441** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 61 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Talimogene laherparepvec

## Key facts

- **NCT ID:** NCT02014441
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2016-01-25
- **Final completion:** 2018-04-19
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014441, "Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02014441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*